A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Noëlle Warmenhoven(Lund University), Oskar Hansson(Eli Lilly (United States)), Alexa Pichet Binette(Lund University), Divya Bali(Malmö University), Randall J. Bateman(Washington University in St. Louis), Kaj Blennow(Sahlgrenska University Hospital), Carlos Cruchaga(Washington University in St. Louis), Niklas Mattsson(Malmö University), Burak Arslan(Sahlgrenska University Hospital), Anna Orduña Dolado(Lund University), Gemma Salvadó(Lund University), Cyrus A. Raji(Washington University in St. Louis), Gallen Triana‐Baltzer(Johnson & Johnson (United States)), Nicolas R. Barthélemy(Washington University in St. Louis), Hartmuth C. Kolb(Johnson & Johnson (United States)), Laura Ibáñez(Washington University in St. Louis), Suzanne E. Schindler(Washington University in St. Louis), Henrik Zetterberg(University of Wisconsin–Madison), Andrew J. Aschenbrenner(Washington University in St. Louis), Jigyasha Timsina(Washington University in St. Louis), Tammie L.S. Benzinger(Washington University in St. Louis), Shorena Janelidze(Lund University), Nicholas J. Ashton(King's College London)
Cited by 95
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k